Who Exports Temozolomide from India — 133 Suppliers Behind a $23.5M Market
India's temozolomide export market is supplied by 133 active exporters who collectively shipped $23.5M across 1,261 shipments. SUN PHARMACEUTICAL INDUSTRIES LIMITED leads with a 62.4% market share, followed by SUN PHARMACEUTICAL INDUSTRIES LTD and JODAS EXPOIM PRIVATE LIMITED. The top 5 suppliers together control 89.8% of total export value, reflecting a concentrated market structure.
Top Temozolomide Exporters from India — Ranked by Export Value
SUN PHARMACEUTICAL INDUSTRIES LIMITED is the leading temozolomide exporter from India, holding a 62.4% share of the $23.5M market across 1,261 shipments from 133 exporters. The top 5 suppliers — SUN PHARMACEUTICAL INDUSTRIES LIMITED, SUN PHARMACEUTICAL INDUSTRIES LTD, JODAS EXPOIM PRIVATE LIMITED, RELIANCE LIFE SCIENCES PRIVATE LIMITED, INTAS PHARMACEUTICALS LIMITED — collectively control 89.8% of total export value, indicating a highly concentrated market. Individual shares are: SUN PHARMACEUTICAL INDUSTRIES LIMITED (62.4%), SUN PHARMACEUTICAL INDUSTRIES LTD (8.4%), JODAS EXPOIM PRIVATE LIMITED (8.4%), RELIANCE LIFE SCIENCES PRIVATE LIMITED (7.1%), INTAS PHARMACEUTICALS LIMITED (3.5%).
Top Temozolomide Exporters from India
Ranked by export value · 133 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | SUN PHARMACEUTICAL INDUSTRIES LIMITED TARO-TEMOZOLOMIDE 100MG CAPSULES [16414PACK X 1X5]TARO-TEMOZOLOMIDE 140 MG CAPSULE BATCH :TARO-TEMOZOLOMIDE 140 MG CAPSULE PACK :01*05 | $14.7M | 8 | 62.4% |
| 2 | SUN PHARMACEUTICAL INDUSTRIES LTD TARO-TEMOZOLOMIDE 100MG CAPSULES [16414PACK X 1X5]TARO-TEMOZOLOMIDE 140 MG CAPSULE BATCH :TARO-TEMOZOLOMIDE 140 MG CAPSULE PACK :01*05 | $2.0M | 4 | 8.4% |
| 3 | JODAS EXPOIM PRIVATE LIMITED TEMOZOLOMIDE LYOPHILISATE FOR PREPARATIOTEMOZOLOMIDE CAPSULES 100MG NOSTEMOZOLOMIDE CAPSULES 100MG [TEMOMID] | $2.0M | 5 | 8.4% |
| 4 | RELIANCE LIFE SCIENCES PRIVATE LIMITED TARO-TEMOZOLOMIDE 100MG CAPSULES [16414PACK X 1X5]TARO-TEMOZOLOMIDE 140 MG CAPSULE BATCH :TARO-TEMOZOLOMIDE 140 MG CAPSULE PACK :01*05 | $1.7M | 14 | 7.1% |
| 5 | INTAS PHARMACEUTICALS LIMITED TEMOZOLOMIDE CAPSULES 180 MGTEMOZOLOMIDE CAPSULES USP 100 MG PACK 5S STRIPTEMOZOLOMIDE 100 MG CAPSULE PACK : 5S STRIP NOS | $825.2K | 9 | 3.5% |
| 6 | ACCURE LABS PRIVATE LIMITED TEMOZOLOMIDE ZENITH 100 MG B5TEMOZOLOMIDE ZENITH 100 MG B5 PRIVATE TEMOZOLOMIDE 100 MGTEMOZOLOMIDE ZENITH 100MG B5 NOS | $631.0K | 1 | 2.7% |
| 7 | INTAS PHARMACEUTICALS LTD TEMOZOLOMIDE CAPSULES 180 MGTEMOZOLOMIDE CAPSULES USP 100 MG PACK 5S STRIPTEMOZOLOMIDE 100 MG CAPSULE PACK : 5S STRIP NOS | $580.0K | 6 | 2.5% |
| 8 | EUGIA PHARMA SPECIALITIES LIMITED TEMOZOLOMIDE CAPSULES 180 MGTEMOZOLOMIDE CAPSULES USP 100 MG PACK 5S STRIPTEMOZOLOMIDE 100 MG CAPSULE PACK : 5S STRIP NOS | $387.0K | 1 | 1.6% |
| 9 | S.D.PHARMACEUTICALS | $156.4K | 1 | 0.7% |
| 10 | CAPLIN ONE LABS LIMITED | $62.3K | 2 | 0.3% |
| 11 | BETA DRUGS LIMITED | $43.1K | 6 | 0.2% |
| 12 | GENEX PHARMA | $34.7K | 1 | 0.1% |
| 13 | KAMAL INTERNATIONAL DIVISION OF GAJHAM EXPORTS PRI | $28.5K | 1 | 0.1% |
| 14 | GETWELL PHARMACEUTICALS | $27.6K | 4 | 0.1% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Temozolomide exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | Warning Letter issued in | Yes, certified in Ap | Yes | 89 approvals as of August 2018 | FDA Warning Letter cited CGMP violations at Dadra facility in June 2024. |
| Intas Pharmaceuticals Limited | Not Listed | Yes, certified in Ap | Yes | Not Listed | WHO-GMP certified in April 2007; no FDA Warning Letters found. |
TransData Nexus reviewed the regulatory standing of 2 leading Temozolomide exporters from India. 0 hold US FDA facility approvals, 2 maintain WHO-GMP certification, and 2 are EU GMP compliant. 1 supplier has received FDA regulatory actions — buyers should verify current remediation status before placing orders. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Temozolomide sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is renowned for its extensive production of active pharmaceutical ingredients (APIs). The city's pharmaceutical ecosystem is supported by numerous API manufacturers and research institutions, fostering innovation and large-scale production. Companies in Hyderabad are instrumental in supplying high-quality APIs, including those for oncology drugs like Temozolomide, to both domestic and international markets.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat has emerged as a significant hub for pharmaceutical formulations. This region hosts several leading pharmaceutical companies specializing in the development and manufacturing of finished dosage forms. The presence of state-of-the-art facilities and a skilled workforce enables the production of complex formulations, including Temozolomide capsules, meeting stringent global regulatory standards.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt serves as a crucial export gateway for India's pharmaceutical products. With its proximity to major ports and well-established logistics infrastructure, this region facilitates the efficient export of pharmaceuticals to international markets. Companies operating here are adept at navigating global regulatory requirements, ensuring timely delivery of products like Temozolomide to countries worldwide.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi-Nalagarh in Himachal Pradesh is known for its favorable tax incentives, attracting numerous pharmaceutical manufacturers. The region offers benefits such as tax holidays and reduced excise duties, making it an attractive destination for setting up manufacturing units. These incentives have led to the establishment of facilities producing a wide range of pharmaceuticals, including oncology drugs like Temozolomide.
5Sourcing Recommendations
- Diversify Supplier Base: While major suppliers like Sun Pharmaceutical Industries Limited dominate the market, consider engaging with other reputable manufacturers to mitigate supply chain risks.
- Assess Manufacturing Capabilities: Evaluate potential suppliers' compliance with international quality standards, such as WHO-GMP and USFDA approvals, to ensure product quality and regulatory adherence.
- Leverage Regional Strengths: Utilize the specific strengths of each pharmaceutical cluster—such as API production in Hyderabad and formulation expertise in Ahmedabad-Vadodara—to optimize sourcing strategies.
- Monitor Export Trends: Stay informed about export data and market dynamics to identify emerging suppliers and assess the competitive landscape for Temozolomide.
By strategically engaging with India's diverse pharmaceutical clusters and adhering to these recommendations, TransData Nexus can enhance its supply chain resilience and ensure a steady supply of high-quality Temozolomide.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Temozolomide exporters from India
Sun Pharmaceutical Industries Limited — Sun Pharma acquires Concert Pharmaceuticals for $576 million
On March 6, 2023, Sun Pharmaceutical Industries Limited completed the acquisition of Concert Pharmaceuticals, Inc., a U.S.-based biotechnology company specializing in treatments for alopecia areata. IMPACT: This acquisition is expected to enhance Sun Pharma's research capabilities, potentially leading to expanded production and export of oncology drugs, including Temozolomide.
Impact: This acquisition is expected to enhance Sun Pharma's research capabilities, potentially leading to expanded production and export of oncology drugs, including Temozolomide.
Sun Pharmaceutical Industries Limited — Sun Pharma acquires Checkpoint Therapeutics for $355 million
In March 2025, Sun Pharmaceutical Industries Limited announced the acquisition of Checkpoint Therapeutics, a U.S.-based company focused on immunotherapy and targeted oncology treatments. IMPACT: This acquisition is anticipated to strengthen Sun Pharma's oncology portfolio, potentially increasing the export of oncology drugs, including Temozolomide.
Impact: This acquisition is anticipated to strengthen Sun Pharma's oncology portfolio, potentially increasing the export of oncology drugs, including Temozolomide.
Intas Pharmaceuticals Limited — Intas acquires Teva's UK & Ireland assets for $764 million
In October 2016, Intas Pharmaceuticals Limited acquired the UK and Ireland assets of Teva Pharmaceuticals for $764 million, marking a significant expansion into the European market. IMPACT: This acquisition enhanced Intas's manufacturing capabilities and market reach, potentially increasing the export of generic drugs, including Temozolomide.
Impact: This acquisition enhanced Intas's manufacturing capabilities and market reach, potentially increasing the export of generic drugs, including Temozolomide.
Common Questions — Temozolomide Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which temozolomide supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, SUN PHARMACEUTICAL INDUSTRIES LIMITED leads with 311 recorded shipments worth $14.7M. SUN PHARMACEUTICAL INDUSTRIES LTD (19 shipments) and JODAS EXPOIM PRIVATE LIMITED (35 shipments) are also established high-volume exporters.
Q How many temozolomide manufacturers are there in India?
India has 133 active temozolomide exporters with a combined export market of $23.5M across 1,261 shipments to 90 countries. The top 5 suppliers hold 89.8% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for temozolomide from India?
Average FOB unit price: $18.75 per unit, ranging from $0.01 to $6092.57. Average shipment value: $18.6K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 133 verified Indian exporters of Temozolomide ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 1,261 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 90 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
1,261 Verified Shipments
133 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists